ERBB2 and carcinoma: The proportion of HER2-positive MBC was slightly lower in our cohort, with 4.4% compared to 8% in the larger cohort by Cardoso et al. However, our analysis is the first reporting, particularly the proportion of HER2-low carcinomas among MBC, which is higher than in the Austrian AGMT_MBC registry [20].